Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.

Ambre Deniniolle, Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Alice Garnier, Sophie Vantyghem, Aude-Marie Fourmont, Pierre Peterlin, Patrice Chevallier

Blood (2025) 146 (Supplement 1): 7785.

https://doi.org/10.1182/blood-2025-7785

Published: 2025

Journal Articles

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Blood (2025) 146 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2025-1682

Published: 2025

Journal Articles

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

Blood (2025) 146 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2025-1658

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 43.

https://doi.org/10.1182/blood-2025-43

Published: 2025

Journal Articles

First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study.

Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Thierry Guillaume, Sophie Vantyghem, Aude-Marie Fourmont, Yannick Le Bris, Olivier Theisen, Marion Eveillard, Maxime Jullien, Alexandra Jobert, Cloe Geay, Joëlle Gaschet, Patrice Chevallier

Blood (2025) 146 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2025-5193

Published: 2025

Journal Articles

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 881.

https://doi.org/10.1182/blood-2025-881

Published: 2025

Journal Articles

γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction

Sylvain Garciaz, Pierre-Yves Dumas, Pierre Peterlin, Daniel Morillo, Jose Miguel Torregrosa Diaz, Matthew Ulrickson, Agustin Penedo, Aude De Gassart, Emmanuel Valentin, Maelle Mairesse, George Saad, Patrick Brune, Katrien Lemmens, Noemi Angelosanto, Daniel Olive, Stephan Braun, Naval Daver, Abhishek Maiti

Blood (2025) 146 (Supplement 1): 652.

https://doi.org/10.1182/blood-2025-652

Published: 2025

Journal Articles

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Blood (2025) 146 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2025-5247

Published: 2025

Journal Articles

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Blood (2025) 146 (Supplement 1): 5225.

https://doi.org/10.1182/blood-2025-5225

Published: 2025

Journal Articles

Frequency and impact of FLT3-ITD microclones in younger AML patients

Blood (2025) 146 (Supplement 1): 456.

https://doi.org/10.1182/blood-2025-456

Published: 2025

Journal Articles

High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission.

Blood (2025) 146 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2025-5295

Published: 2025

Journal Articles

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Blood (2025) 146 (Supplement 1): 3455.

https://doi.org/10.1182/blood-2025-3455

Published: 2025

Journal Articles

Relationship between salvage strategy and outcomes in patients with CBF or NPM1-mutated AML and first molecular relapse

Blood (2025) 146 (Supplement 1): 347.

https://doi.org/10.1182/blood-2025-347

Published: 2025

Journal Articles

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2025) 145 (11): 1126–1135.

https://doi.org/10.1182/blood.2024025464

Published: 2025

Includes: Supplemental data

Journal Articles

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Blood (2024) 144 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2024-201317

Published: 2024

Journal Articles

Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

Valentin Letailleur, Maxime Jullien, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Sophie Vantyghem, Aude-Marie Fourmont, Thierry Guillaume, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2024-203972

Published: 2024

Journal Articles

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Laura Prin Felix, Maxime Jullien, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Sophie Vantyghem, Aude-Marie Fourmont, Thierry Guillaume, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2024-203266

Published: 2024

Journal Articles

Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin

Maxime Jullien, Catherine Willem, Perla Salameh, Enora Ferron, Alice Garnier, Pierre Peterlin, Amandine Le Bourgeois, Thierry Guillaume, Katia Gagne, Patrice Chevallier, Christelle Retiere

Blood (2024) 144 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2024-202902

Published: 2024

Journal Articles

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Blood (2024) 144 (Supplement 1): 2905.

https://doi.org/10.1182/blood-2024-209998

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study.

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Frequency and impact of FLT3-ITD microclones in younger AML patients

High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission.

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Relationship between salvage strategy and outcomes in patients with CBF or NPM1-mutated AML and first molecular relapse

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only